Remission and Recovery in the Treatment for Adolescents With Depression Study (TADS): Acute and Long-Term Outcomes
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective We examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS). Method TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder (MDD) to 12 weeks of treatment to fluoxetine (FLX), cognitive behavioral therapy (CBT), their combination (COMB), or pill placebo (PBO). The PBO group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at week 12 (acute phase remitters) and week 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission. Results At Week 36, the estimated remission rates for intention-to-treat cases were: COMB: 60%, FLX: 55%; CBT: 64%; overall: 60%. Paired comparisons reveal that at week 24 all active treatments converge on remission outcomes. The recovery rate at Week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36. Conclusions The majority of depressed adolescents in all three treatment modalities achieved remission at the end of nine months of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
Subthreshold Depression in Adolescence and Mental Health Outcomes in Adulthood
Fergusson, D. M., Horwood, L. J., Ridder, E. M., & Beautrais, A. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.66 · Cited by 792
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Brent, D. A. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830210125017 · Cited by 753
(2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1132 · Cited by 752
Self-citationPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Cited by
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Karyotaki, E., Ebert, D. D., Donkin, L., Riper, H., Twisk, J., Burger, S., Rozental, A., Lange, A., Williams, A. D., Zarski, A. C., et al. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.007 · Cited by 303
“, 1997), lower relapse rates, and improved longterm prognosis (Bech, Lönn, & Overø, 2010; Fava, Fabbri, & Sonino, 2002; Karp et al., 2004; Kennard et al., 2009; Ogrodniczuk, Piper, & Joyce, 2004; Taylor, Walters, Vittengl, Krebaum, & Jarrett, 2010).”
Is there an association between diet and depression in children and adolescents? A systematic review
Khalid, S., Williams, C. M., & Reynolds, S. A. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516004359 · Cited by 276
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes
Emslie, G. J., Mayes, T., Porta, G., Vitiello, B., Clarke, G., Wagner, K. D., Asarnow, J. R., Spirito, A., Birmaher, B., Ryan, N., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09040552 · Cited by 217
Self-citationKennard, B. D., Emslie, G. J., Mayes, T. L., Nakonezny, P. A., Jones, J. M., Foxwell, A. A., & King, J. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111460 · Cited by 134
Self-citationRice, S., Gleeson, J., Davey, C., Hetrick, S., Parker, A., Lederman, R., Wadley, G., Murray, G., Herrman, H., Chambers, R., et al. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12354 · Cited by 118
Neural Correlates of Antidepressant Treatment Response in Adolescents with Major Depressive Disorder
Cullen, K. R., Klimes-Dougan, B., Vu, D. P., Westlund Schreiner, M., Mueller, B. A., Eberly, L. E., Camchong, J., Westervelt, A., & Lim, K. O. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0232 · Cited by 75
“Major depressive disorder (MDD) is common in adolescentsand is associated with high risk of recurrence, comorbidity, future disability, and suicide (Weissman et al. 1997; Ustün et al. 2004; Zisook et al. 2004, 2007; Kennard et al. 2009).”
BackgroundDietz, L. J., Weinberg, R. J., Brent, D. A., & Mufson, L. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.011 · Cited by 74
Vitiello, B., Brent, D. A., Greenhill, L. L., Emslie, G., Wells, K., Walkup, J. T., Stanley, B., Bukstein, O., Kennard, B. D., Compton, S., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b5db66 · Cited by 72
Self-citationCroarkin, P. E., Nakonezny, P. A., Husain, M. M., Melton, T., Buyukdura, J. S., Kennard, B. D., Emslie, G. J., Kozel, F. A., & Daskalakis, Z. J. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.24 · Cited by 65
“Current treatment is challenging because of the poor understanding of relevant pathophysiology(5) and suboptimal remission rates with standard treatments.(6) Recent controversy about the safety of selective serotonin reuptake inhibitors in young patients also underscores the necessity for a greater awareness of the un…”
Self-citationCourtney, D. B., Watson, P., Krause, K. R., Chan, B. W. C., Bennett, K., Gunlicks-Stoessel, M., Rodak, T., Neprily, K., Zentner, T., & Szatmari, P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46331 · Cited by 63
Patel, D. R., Feucht, C., Brown, K., & Ramsay, J. (2018) · Translational Pediatrics · doi:10.21037/tp.2017.08.05 · Cited by 62
Findling, R. L., Robb, A., & Bose, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0023 · Cited by 57
“These rates appear to be comparable to the remission rates for escitalopram within a similar time frame, and the fluoxetine results suggest increasing remission with longer duration of treatment (Kennard et al. 2009).”
BackgroundResultCox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48
Self-citationOestergaard, S., & Møldrup, C. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.014 · Cited by 38
Outcome of depressive mood disorder among adolescent outpatients in an eight-year follow-up
Kiviruusu, O., Strandholm, T., Karlsson, L., & Marttunen, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.174 · Cited by 34
Chronotherapeutic treatments for depression in youth
Gest, S., Holtmann, M., Bogen, S., Schulz, C., Pniewski, B., & Legenbauer, T. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0720-6 · Cited by 32
Davidson, T. M., Yuen, E. K., Felton, J. W., McCauley, J., Gros, K. S., & Ruggiero, K. J. (2014) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.48.1.f · Cited by 24
“Efficacious treatment options exist for depressed adolescents [10], but less than half of all youths with a mental disorder access formal treatment services [11].”
BackgroundJoy Returns Last: Anhedonia and Treatment Resistance in Depressed Adolescents
Rubin, D. H. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.012 · Cited by 21
Metadata
- Authors
- Kennard, B. D., Silva, S. G., Tonev, S., Rohde, P., Hughes, J. L., Vitiello, B., Kratochvil, C. J., Curry, J. F., Emslie, G. J., Reinecke, M., & March, J.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 48
- Issue
- 2
- Pages
- 186-195
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2054702712
- Cited by
- 190
- References
- 19
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.